关于拒绝至少k个假设的holm相关MTP:一般效度、最优性、置信区域和应用。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Olivier J M Guilbaud
{"title":"关于拒绝至少k个假设的holm相关MTP:一般效度、最优性、置信区域和应用。","authors":"Olivier J M Guilbaud","doi":"10.1080/10543406.2024.2429478","DOIUrl":null,"url":null,"abstract":"<p><p>This article concerns <i>p</i>-value-based multiple testing procedures (MTPs) that can be used in a confirmatory clinical study under minimal assumptions in case the requirement for study-success is that at least <i>k</i> out of <i>m</i> primary/important hypotheses become rejected. Recently, a simple, generally valid Holm-type MTP was discussed that can be used for such a requirement for any <i>k</i> from one to <i>m</i>. It can only reject at least <i>k</i> (or zero) hypotheses, but this increases the power to reject <i>k</i> or more hypotheses compared to Holm's step-down MTP. The present article provides a simple formulation and proof of strong family-wise error rate (FWER) control for a stepwise MTP that is sharper in that for any <i>k</i> strictly between one and <i>m</i> it: (a) always rejects at least as much, and (b) can potentially reject fewer than <i>k</i> hypotheses. This sharper MTP too is generally valid, without any assumption about logical or stochastic relationships. It has a gatekeeping step, followed by <i>m</i> steps where ordered primary <i>p</i>-values are compared to critical constants and rejections are made in a step-down manner. These constants have the optimality property that under a natural monotonicity restriction, they cannot be increased without losing the general strong FWER control. Confidence regions like those for Holm's MTP are provided. Applications are discussed in connection with three interesting approaches proposed earlier for confirmatory studies: (a) the Superiority-Noninferiority approach; (b) Fallback tests for co-primary endpoints; and (c) Multistage gatekeeping MTPs that utilize so-called <i>k</i>-truncated Holm MTPs in some stages.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-19"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"On a Holm-related MTP for rejecting at least <i>k</i> hypotheses: general validity, optimality property, confidence regions, and applications.\",\"authors\":\"Olivier J M Guilbaud\",\"doi\":\"10.1080/10543406.2024.2429478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This article concerns <i>p</i>-value-based multiple testing procedures (MTPs) that can be used in a confirmatory clinical study under minimal assumptions in case the requirement for study-success is that at least <i>k</i> out of <i>m</i> primary/important hypotheses become rejected. Recently, a simple, generally valid Holm-type MTP was discussed that can be used for such a requirement for any <i>k</i> from one to <i>m</i>. It can only reject at least <i>k</i> (or zero) hypotheses, but this increases the power to reject <i>k</i> or more hypotheses compared to Holm's step-down MTP. The present article provides a simple formulation and proof of strong family-wise error rate (FWER) control for a stepwise MTP that is sharper in that for any <i>k</i> strictly between one and <i>m</i> it: (a) always rejects at least as much, and (b) can potentially reject fewer than <i>k</i> hypotheses. This sharper MTP too is generally valid, without any assumption about logical or stochastic relationships. It has a gatekeeping step, followed by <i>m</i> steps where ordered primary <i>p</i>-values are compared to critical constants and rejections are made in a step-down manner. These constants have the optimality property that under a natural monotonicity restriction, they cannot be increased without losing the general strong FWER control. Confidence regions like those for Holm's MTP are provided. Applications are discussed in connection with three interesting approaches proposed earlier for confirmatory studies: (a) the Superiority-Noninferiority approach; (b) Fallback tests for co-primary endpoints; and (c) Multistage gatekeeping MTPs that utilize so-called <i>k</i>-truncated Holm MTPs in some stages.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-19\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-12-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2024.2429478\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2429478","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

本文涉及基于p值的多重测试程序(mtp),如果研究成功的要求是m个主要/重要假设中至少有k个被拒绝,则可以在最小假设下用于验证性临床研究。最近,我们讨论了一个简单的,普遍有效的Holm型MTP,它可以用于从1到m的任何k的要求。它只能拒绝至少k(或0)个假设,但与Holm的降压MTP相比,这增加了拒绝k或更多假设的能力。本文提供了一个简单的公式和证明,用于逐步MTP的强家庭误差率(FWER)控制,对于严格介于1和m之间的任何k,它都更尖锐:(a)总是拒绝至少同样多,并且(b)可能拒绝少于k个假设。这种更清晰的MTP通常也是有效的,不需要任何关于逻辑或随机关系的假设。它有一个把关步骤,接下来是m个步骤,其中有序的主p值与关键常数进行比较,并以逐步下降的方式进行拒绝。这些常数具有最优性,即在自然单调性限制下,它们不能在不失去一般强FWER控制的情况下增加。提供了像Holm的MTP那样的信心区域。应用程序讨论与之前提出的验证性研究的三种有趣的方法:(a)优势-非劣效性方法;(b)共同主要终点的后备试验;(c)在某些阶段利用所谓的k截断霍尔姆MTPs的多级守门MTPs。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
On a Holm-related MTP for rejecting at least k hypotheses: general validity, optimality property, confidence regions, and applications.

This article concerns p-value-based multiple testing procedures (MTPs) that can be used in a confirmatory clinical study under minimal assumptions in case the requirement for study-success is that at least k out of m primary/important hypotheses become rejected. Recently, a simple, generally valid Holm-type MTP was discussed that can be used for such a requirement for any k from one to m. It can only reject at least k (or zero) hypotheses, but this increases the power to reject k or more hypotheses compared to Holm's step-down MTP. The present article provides a simple formulation and proof of strong family-wise error rate (FWER) control for a stepwise MTP that is sharper in that for any k strictly between one and m it: (a) always rejects at least as much, and (b) can potentially reject fewer than k hypotheses. This sharper MTP too is generally valid, without any assumption about logical or stochastic relationships. It has a gatekeeping step, followed by m steps where ordered primary p-values are compared to critical constants and rejections are made in a step-down manner. These constants have the optimality property that under a natural monotonicity restriction, they cannot be increased without losing the general strong FWER control. Confidence regions like those for Holm's MTP are provided. Applications are discussed in connection with three interesting approaches proposed earlier for confirmatory studies: (a) the Superiority-Noninferiority approach; (b) Fallback tests for co-primary endpoints; and (c) Multistage gatekeeping MTPs that utilize so-called k-truncated Holm MTPs in some stages.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信